Trial Profile
Low‑dose bevacizumab with weekly irinotecan for platinum‑ and taxanes‑resistant epithelial ovarian cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 28 Oct 2015 New trial record